Cargando…
Adrenocortical Carcinoma and CT Assessment of Therapy Response: The Value of Combining Multiple Criteria
We evaluated tumor response at Computed Tomography (CT) according to three radiologic criteria: RECIST 1.1, CHOI and tumor volume in 34 patients with metastatic adrenocortical carcinoma (ACC) submitted to standard chemotherapy. These three criteria agreed in defining partial response, stable or prog...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352253/ https://www.ncbi.nlm.nih.gov/pubmed/32481732 http://dx.doi.org/10.3390/cancers12061395 |
_version_ | 1783557594574487552 |
---|---|
author | Ambrosini, Roberta Balli, Maria Carolina Laganà, Marta Bertuletti, Martina Bottoni, Luca Vaccher, Filippo Cosentini, Deborah Di Terlizzi, Marco Sigala, Sandra Grisanti, Salvatore Tiberio, Guido Alberto Massimo Berruti, Alfredo Grazioli, Luigi |
author_facet | Ambrosini, Roberta Balli, Maria Carolina Laganà, Marta Bertuletti, Martina Bottoni, Luca Vaccher, Filippo Cosentini, Deborah Di Terlizzi, Marco Sigala, Sandra Grisanti, Salvatore Tiberio, Guido Alberto Massimo Berruti, Alfredo Grazioli, Luigi |
author_sort | Ambrosini, Roberta |
collection | PubMed |
description | We evaluated tumor response at Computed Tomography (CT) according to three radiologic criteria: RECIST 1.1, CHOI and tumor volume in 34 patients with metastatic adrenocortical carcinoma (ACC) submitted to standard chemotherapy. These three criteria agreed in defining partial response, stable or progressive disease in 24 patients (70.5%). Partial response (PR) was observed in 29.4%, 29.4% and 41.2% of patients according to RECIST 1.1, CHOI and tumor volume, respectively. It was associated with a favorable prognosis, regardless of the criterion adopted. The concordance of all the 3 criteria in defining the disease response identified 8 patients (23.5%) which displayed a very good prognosis: median progression free survival (PFS) and overall survival (OS) 14.9 and 37.7 months, respectively. Seven patients (20.6%) with PR assessed by one or two criteria, however, still had a better prognosis than non-responding patients, both in terms of PFS: median 12.3 versus 9.9 months and OS: 21 versus 12.2, respectively. In conclusions, the CT assessment of disease response of ACC patients to chemotherapy with 3 different criteria is feasible and allows the identification of a patient subset with a more favorable outcome. PR with at least one criterion can be useful to early identify patients that deserve continuing the therapy. |
format | Online Article Text |
id | pubmed-7352253 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-73522532020-07-21 Adrenocortical Carcinoma and CT Assessment of Therapy Response: The Value of Combining Multiple Criteria Ambrosini, Roberta Balli, Maria Carolina Laganà, Marta Bertuletti, Martina Bottoni, Luca Vaccher, Filippo Cosentini, Deborah Di Terlizzi, Marco Sigala, Sandra Grisanti, Salvatore Tiberio, Guido Alberto Massimo Berruti, Alfredo Grazioli, Luigi Cancers (Basel) Article We evaluated tumor response at Computed Tomography (CT) according to three radiologic criteria: RECIST 1.1, CHOI and tumor volume in 34 patients with metastatic adrenocortical carcinoma (ACC) submitted to standard chemotherapy. These three criteria agreed in defining partial response, stable or progressive disease in 24 patients (70.5%). Partial response (PR) was observed in 29.4%, 29.4% and 41.2% of patients according to RECIST 1.1, CHOI and tumor volume, respectively. It was associated with a favorable prognosis, regardless of the criterion adopted. The concordance of all the 3 criteria in defining the disease response identified 8 patients (23.5%) which displayed a very good prognosis: median progression free survival (PFS) and overall survival (OS) 14.9 and 37.7 months, respectively. Seven patients (20.6%) with PR assessed by one or two criteria, however, still had a better prognosis than non-responding patients, both in terms of PFS: median 12.3 versus 9.9 months and OS: 21 versus 12.2, respectively. In conclusions, the CT assessment of disease response of ACC patients to chemotherapy with 3 different criteria is feasible and allows the identification of a patient subset with a more favorable outcome. PR with at least one criterion can be useful to early identify patients that deserve continuing the therapy. MDPI 2020-05-28 /pmc/articles/PMC7352253/ /pubmed/32481732 http://dx.doi.org/10.3390/cancers12061395 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ambrosini, Roberta Balli, Maria Carolina Laganà, Marta Bertuletti, Martina Bottoni, Luca Vaccher, Filippo Cosentini, Deborah Di Terlizzi, Marco Sigala, Sandra Grisanti, Salvatore Tiberio, Guido Alberto Massimo Berruti, Alfredo Grazioli, Luigi Adrenocortical Carcinoma and CT Assessment of Therapy Response: The Value of Combining Multiple Criteria |
title | Adrenocortical Carcinoma and CT Assessment of Therapy Response: The Value of Combining Multiple Criteria |
title_full | Adrenocortical Carcinoma and CT Assessment of Therapy Response: The Value of Combining Multiple Criteria |
title_fullStr | Adrenocortical Carcinoma and CT Assessment of Therapy Response: The Value of Combining Multiple Criteria |
title_full_unstemmed | Adrenocortical Carcinoma and CT Assessment of Therapy Response: The Value of Combining Multiple Criteria |
title_short | Adrenocortical Carcinoma and CT Assessment of Therapy Response: The Value of Combining Multiple Criteria |
title_sort | adrenocortical carcinoma and ct assessment of therapy response: the value of combining multiple criteria |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352253/ https://www.ncbi.nlm.nih.gov/pubmed/32481732 http://dx.doi.org/10.3390/cancers12061395 |
work_keys_str_mv | AT ambrosiniroberta adrenocorticalcarcinomaandctassessmentoftherapyresponsethevalueofcombiningmultiplecriteria AT ballimariacarolina adrenocorticalcarcinomaandctassessmentoftherapyresponsethevalueofcombiningmultiplecriteria AT laganamarta adrenocorticalcarcinomaandctassessmentoftherapyresponsethevalueofcombiningmultiplecriteria AT bertulettimartina adrenocorticalcarcinomaandctassessmentoftherapyresponsethevalueofcombiningmultiplecriteria AT bottoniluca adrenocorticalcarcinomaandctassessmentoftherapyresponsethevalueofcombiningmultiplecriteria AT vaccherfilippo adrenocorticalcarcinomaandctassessmentoftherapyresponsethevalueofcombiningmultiplecriteria AT cosentinideborah adrenocorticalcarcinomaandctassessmentoftherapyresponsethevalueofcombiningmultiplecriteria AT diterlizzimarco adrenocorticalcarcinomaandctassessmentoftherapyresponsethevalueofcombiningmultiplecriteria AT sigalasandra adrenocorticalcarcinomaandctassessmentoftherapyresponsethevalueofcombiningmultiplecriteria AT grisantisalvatore adrenocorticalcarcinomaandctassessmentoftherapyresponsethevalueofcombiningmultiplecriteria AT tiberioguidoalbertomassimo adrenocorticalcarcinomaandctassessmentoftherapyresponsethevalueofcombiningmultiplecriteria AT berrutialfredo adrenocorticalcarcinomaandctassessmentoftherapyresponsethevalueofcombiningmultiplecriteria AT grazioliluigi adrenocorticalcarcinomaandctassessmentoftherapyresponsethevalueofcombiningmultiplecriteria |